Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc at Canaccord Genuity Growth Conference (Virtual) Transcript

Aug 13, 2020 / 05:00PM GMT
Michelle Lim Gilson
Canaccord Genuity Corp., Research Division - Analyst

Hello, everyone. Good afternoon, and thank you for joining us today. My name is Michelle Gilson. I'm one of the biotech analysts here at Canaccord Genuity. I'm super excited to welcome Hank Fuchs, the President of Worldwide Research and Development; and Brian Mueller, Chief Financial Officer, here from BioMarin, today for a fireside chat. To start us off, I am going to pass it off to Brian for some opening remarks.

Henry J. Fuchs
BioMarin Pharmaceutical Inc. - President of Worldwide Research & Development

Thanks, Michelle. We appreciate the opportunity to participate in your virtual conference. 2020 is truly a transformational year for BioMarin. For the first time in our history, we expect for the profitable for the full year of a GAAP basis despite the challenges brought about by COVID-19. We've positioned ourselves well to drive significant growth beyond our established base business with the potential additions of both ROCTAVIAN gene therapy for hemophilia A and vosoritide for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot